The demand for therapies and vaccines is forcing manufacturers to accelerate the development of biologic antibody production processes and bring drugs to market faster. Preventing the spread of COVID-19 is the most recent example of these efforts.
But working with drug products is costly. It can be expensive to maximize or change processes once it gets approved. And the materials involved aren’t cheap. The more work that can be simulated on a computer, the more analysis is possible without disrupting a plant or a process. It makes the system more efficient.
Yet, this was not possible 10 years ago. That was when GPU, or graphical processing unit-based computing, was less robust and not capable of handling the workload. Hardware advancements have changed that, making simulations like digital twin modeling possible. This move towards digitization and digital twins is not a fad or engineering trend, but rather the way processes will be designed and optimized in the future.
Case in point: The largest pharma manufacturers have already adopted the technology, and smaller industry players aren’t far behind.
